Veranova A CDMO that manages complexity with confidence

Veranova A CDMO that manages complexity with confidence

X

Find Clinical Drug Pipeline Developments & Deals by Autifony Therapeutics

Autifony Therapeutics

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

No Content

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Autifony Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme

Details:

Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Autifony has regained full rights to its Kv3 programme.

Lead Product(s): AUT00206

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AUT00206

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

Deal Size: $50.1 million Upfront Cash: $29.5 million

Deal Type: Termination August 26, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY